Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management .
Immunotherapy, specifically the use of checkpoint inhibitors, offers patients with cancer an alternative to chemotherapy, targeting different pathways to destroy cancer cells. The side effects of immunotherapies, as well as their impact on normal tissue, need to be assessed and managed based on their mechanisms of action.



This article presents an overview of immune-related adverse events (AEs).  .



Common immune-related toxicities, as well as rare and refractory toxicities, are reviewed.  .



Immunotherapy treatment is an option for many patients with cancer, and nurses must understand the distinct side effect profile of these agents. Prompt identification and expert management are the cornerstones of success when dealing with immune-related AEs, and oncology nurses play a key role in improving patient care.
Memorial Sloan Kettering Cancer Center.
RuthAnn
R
Gordon
Memorial Sloan Kettering Cancer Center.
Mary Kate
MK
Kasler
Memorial Sloan Kettering Cancer Center.
Kristen
K
Stasi
Memorial Sloan Kettering Cancer Center.
Yelena
Y
Shames
Memorial Sloan Kettering Cancer Center.
Mimma
M
Errante
Memorial Sloan Kettering Cancer Center.
Kathryn
K
Ciccolini
Memorial Sloan Kettering Cancer Center.
Anna
A
Skripnik Lucas
Memorial Sloan Kettering Cancer Center.
Pam
P
Raasch
Memorial Sloan Kettering Cancer Center.
Erica
E
Fischer-Cartlidge
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology* / Q000451:nursing*; D004509:Education, Nursing, Continuing; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000451:nursing; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology* / Q000451:nursing*; D008875:Middle Aged; D009859:Oncology Nursing / Q000592:standards*; D017410:Practice Guidelines as Topic
D000911:Antibodies, Monoclonal
cancer immunotherapy, immune-related adverse events, checkpoint inhibitors